Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma
ConclusionsTACE-L proves to be a safe and efficacious conversion therapy modality that allows for secondary resectability in patients with initially unresectable ICC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Cholangiocarcinoma | Drugs & Pharmacology | Investigational New Drugs | Study | Toxicology